[PDF] Top 20 Trabectedin for advanced soft tissue sarcomas: optimizing use

... The design of trials in the second-line setting is made more difficult, as randomized Phase II studies comparing with the current gold standard are often employed and for ASTS there is no consensus about the optimal ... See full document

... with trabectedin commenced which was maintained for 12 ...During trabectedin treatment, the patient maintained an active and busy lifestyle including managing her own affairs as well as support services for ... See full document

... for advanced disease, patients who progressed and received systemic therapy for advanced disease would have been omitted from the cancer-directed therapy ...pazopanib, trabectedin) became available ... See full document

... compassionate use setting where patients typically have received multiple lines of treatment and have limited therapeutic ...the use of pazopanib in routine clinical ... See full document

... Abstract: Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mes- enchymal ...in advanced and metastatic soft tissue sarcomas, with an emphasis ... See full document

... vitro, trabectedin interferes with the binding of this fusion protein to DNA ...translocation-related sarcomas (17/72, ...synovial sarcomas (DCR, 5/10 patients), myxoid round cell liposarcoma (5/6), ... See full document

... Abstract: Soft tissue sarcomas (STSs) are a group of rare tumors accounting for less than 1% of all adult malignant tumors, a heterogeneous group of more than 50 histological ...lacking. ... See full document

... (L-type sarcomas) is cur- rently accruing ...L-type sarcomas is also open in the US to facilitate access to trabectedin in patients unlikely to benefit from other standard- of-care ...of ... See full document

... all soft tissue sarcomas ...the use of gemcitabine/docetaxel in relapsed synovial sarcoma in patients from two tertiary cancer centres; at the Royal Marsden Hospital in London and at the ... See full document

... The answer could be biological in nature, with pazopanib having some inhibitory property that other agents lack. Alternatively, pazopanib may have pharmacodynamic or pharmacokinetic properties that favor its activity. ... See full document

... that trabectedin proapop- totic activity involve mainly P53 ...combined use or trabectedin and rucaparib sig- nificantly increases this ...with trabectedin and rucaparib used as single ... See full document

... The use of imaging modalities that provide information on changes in tumor physiology beyond a dimensional response shows promise for assessing pazopanib effect and represents a potential avenue of delineating the ... See full document

... that trabectedin used as a single agent is not correlated with any grade of toxicity in about 91% of cases, with grade 3 and 4 adverse events occur- ring in only about 10% of ...of trabectedin and tend to ... See full document

... the use of adju- vant radiotherapy being significantly less frequent in the ILP ...the use of radiotherapy following ILP, although it is typically considered following an inadequate response on histo- ... See full document

... with advanced bone and soft tissue sarcomas using ridaforolimus ...bone sarcomas, leiomyosarcomas, liposarcomas, and other soft tissue ... See full document

... 29. Della Vittoria Scarpati G, Perri F, Pisconti S, Costa G, Ricciardiello F, Del Prete S, et al. Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable ... See full document

... Several trabectedin-based combinations have been tested in phase I trials, including combination with cisplatin (Grasselli et al 2007) capecitabine (Gore et al 2006), paclitaxel (Papa- dopoulos et al 2006), ... See full document

... affin-embedded tissue is suitable for RT-PCR to detect and distinguish the two common translo- cation variants ...synovial sarcomas. Recently, gene and tissue microarray studies have identified TLE1 ... See full document

... mal tissue. What constitutes an acceptable margin of normal tissue is not universally agreed but is commonly accepted as 1 cm soft tissue, or equivalent ... See full document

... shown to be predictive of radiotherapy response in pre-clinical studies (7). Recent recommendations have suggested quantitative MRI parameters as exploratory end-points in clinical trials but emphasized the requirement ... See full document